HU9401742D0 - Medicaments for inhalation - Google Patents

Medicaments for inhalation

Info

Publication number
HU9401742D0
HU9401742D0 HU9401742A HU9401742A HU9401742D0 HU 9401742 D0 HU9401742 D0 HU 9401742D0 HU 9401742 A HU9401742 A HU 9401742A HU 9401742 A HU9401742 A HU 9401742A HU 9401742 D0 HU9401742 D0 HU 9401742D0
Authority
HU
Hungary
Prior art keywords
medicaments
inhalation
Prior art date
Application number
HU9401742A
Other languages
English (en)
Other versions
HUT67534A (en
HU227383B1 (en
Inventor
David Andrew Wyatt
Rachel Ann Akehurst
Anthony James Taylor
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU9401742(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919126378A external-priority patent/GB9126378D0/en
Priority claimed from GB919126405A external-priority patent/GB9126405D0/en
Priority claimed from GB929202522A external-priority patent/GB9202522D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HU9401742D0 publication Critical patent/HU9401742D0/hu
Publication of HUT67534A publication Critical patent/HUT67534A/hu
Publication of HU227383B1 publication Critical patent/HU227383B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HU9401742A 1991-12-12 1992-12-04 Medicament for inhalation and canister suitable for its storing and the process for preparations thereof HU227383B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB919126378A GB9126378D0 (en) 1991-12-12 1991-12-12 Medicaments
GB919126405A GB9126405D0 (en) 1991-12-12 1991-12-12 Medicaments
GB929202522A GB9202522D0 (en) 1992-02-06 1992-02-06 Medicaments
PCT/EP1992/002808 WO1993011743A1 (en) 1991-12-12 1992-12-04 Medicaments

Publications (3)

Publication Number Publication Date
HU9401742D0 true HU9401742D0 (en) 1994-09-28
HUT67534A HUT67534A (en) 1995-04-28
HU227383B1 HU227383B1 (en) 2011-05-30

Family

ID=27265965

Family Applications (3)

Application Number Title Priority Date Filing Date
HU0800468A HU227681B1 (en) 1991-12-12 1992-12-04 Medicament for inhalation, canister and device containing the same
HU9401742A HU227383B1 (en) 1991-12-12 1992-12-04 Medicament for inhalation and canister suitable for its storing and the process for preparations thereof
HU95P/P00331P HU211671A9 (en) 1991-12-12 1995-06-22 Medicaments

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0800468A HU227681B1 (en) 1991-12-12 1992-12-04 Medicament for inhalation, canister and device containing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU95P/P00331P HU211671A9 (en) 1991-12-12 1995-06-22 Medicaments

Country Status (30)

Country Link
US (10) US5676929A (hu)
EP (8) EP0756868B1 (hu)
JP (2) JP3026840B2 (hu)
KR (1) KR100278339B1 (hu)
AP (1) AP402A (hu)
AT (7) ATE227975T1 (hu)
AU (1) AU663904C (hu)
BG (3) BG62119B1 (hu)
CA (7) CA2362539C (hu)
CY (6) CY2134B1 (hu)
CZ (1) CZ287039B6 (hu)
DE (8) DE69224656T2 (hu)
DK (7) DK0756868T3 (hu)
ES (7) ES2199739T5 (hu)
GE (1) GEP20002253B (hu)
GR (1) GR3036476T3 (hu)
HK (3) HK1012988A1 (hu)
HU (3) HU227681B1 (hu)
IL (1) IL104068A (hu)
IS (1) IS1709B (hu)
MX (1) MX9207205A (hu)
MY (1) MY109758A (hu)
NO (3) NO307864B1 (hu)
NZ (1) NZ246044A (hu)
OA (1) OA09926A (hu)
PT (6) PT1287820E (hu)
RU (2) RU2129424C1 (hu)
SK (1) SK279920B6 (hu)
TW (1) TW232654B (hu)
WO (1) WO1993011743A1 (hu)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
EP1736147A3 (en) 1991-06-10 2007-10-17 Schering Corporation Non-chlorofluorocarbon aerosol formulations
CA2421976C (en) * 1991-12-12 2004-04-20 Glaxo Group Limited Medicaments
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
JP3280974B2 (ja) * 1991-12-12 2002-05-13 グラクソ、グループ、リミテッド 医 薬
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
EP0617610B1 (en) 1991-12-18 1997-03-19 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US20030103907A1 (en) * 1991-12-18 2003-06-05 Schultz Robert K. Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US5833950A (en) * 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
CZ284203B6 (cs) * 1992-12-09 1998-09-16 Boehringer Ingelheim Pharmaceuticals Inc. Tekutý aerosolový přípravek obsahující léčivo a způsob stabilisace tohoto prostředku
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
WO1994022427A1 (en) * 1993-04-01 1994-10-13 Amgen Inc. Method for preparing drugs to treat dermal disorders
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
GB9507768D0 (en) * 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
ES2214536T3 (es) 1995-04-14 2004-09-16 Smithkline Beecham Corporation Inhalador dosificador de dipropionato de beclometasona.
ES2292526T3 (es) * 1995-04-14 2008-03-16 Smithkline Beecham Corporation Procedimiento para la preparacion de un inhalador dosificador.
CN1142798C (zh) 1995-04-14 2004-03-24 葛兰素惠尔康公司 沙美特罗的计定剂量吸入器
AP960A (en) 1995-04-14 2001-04-20 Glaxo Wellcome Inc Metered dose inhaler for fluticasone propionate.
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
GB9526392D0 (en) 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
DE19652790A1 (de) * 1996-12-18 1998-06-25 Hermes Fabrik Pharm Praeparate Pharmazeutische Zubereitungen
GB9626960D0 (en) 1996-12-27 1997-02-12 Glaxo Group Ltd Valve for aerosol container
EP0998300A1 (en) * 1997-03-18 2000-05-10 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20030103906A1 (en) * 1997-10-14 2003-06-05 Smithkline Beecham Corporation Metered dose inhaler having internal surfaces coated with fluorocarbon polymer
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
DE60001492T2 (de) 1999-04-14 2003-12-18 Glaxo Group Ltd., Greenford Pharmazeutische aerosolformulierung
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
US6479035B1 (en) 1999-09-11 2002-11-12 Smithkline Beecham Corporation Pharmaceutical formulation of fluticasone propionate
GB2385596B (en) * 1999-09-11 2004-03-03 Glaxo Group Ltd Container for pharmaceutical formulation of fluticasone propionate
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
ATE291898T1 (de) * 1999-12-24 2005-04-15 Glaxo Group Ltd Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
AU2000250701B2 (en) 2000-05-22 2004-07-01 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
HUP0302005A3 (en) * 2000-05-23 2006-07-28 Glaxo Group Ltd Aerosol container for formulations of salmeterol xinafoate
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
BR0106942A (pt) * 2000-07-07 2002-06-11 Baxter Int Sistema médico, método e aparelho utilizando mems
AR030516A1 (es) * 2000-08-31 2003-08-20 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
MXPA03005697A (es) * 2000-12-22 2003-10-06 Glaxo Group Ltd Inhalador de dosis medida para xinafoato de salmeterol.
DK1353647T3 (da) * 2000-12-27 2011-06-14 Gilead Sciences Inc Inhalerbar aztreonam til behandling og forebyggelse af bakterielle lungeinfektioner
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
DE10104370A1 (de) * 2001-02-01 2002-08-08 Boehringer Ingelheim Pharma Arzneimittelkompositionen mit geringeren Nebenwirkungen
GB0106046D0 (en) 2001-03-12 2001-05-02 Glaxo Group Ltd Canister
BR0208012A (pt) * 2001-03-20 2004-03-02 Glaxo Group Ltd Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6455028B1 (en) * 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
MXPA03010787A (es) * 2001-05-25 2004-03-02 Pfizer Un agonista del receptor a2a de adenosina en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas.
DE60103527T2 (de) 2001-07-02 2005-06-16 Chiesi Farmaceutici S.P.A. Optimierte Tobramycin-Formulierung zur Aerosolbildung
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
GB0124523D0 (en) * 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
US7931022B2 (en) * 2001-10-19 2011-04-26 Respirks, Inc. Method and apparatus for dispensing inhalator medicament
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
EP1458360B1 (en) 2001-12-19 2011-05-11 Novartis AG Pulmonary delivery of aminoglycosides
DK1471887T3 (da) 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
AU2003226603A1 (en) * 2002-04-19 2003-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
EP1562975A2 (en) * 2002-10-25 2005-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
AU2003293361A1 (en) * 2002-12-18 2004-07-29 Glaxo Group Limited Drug delivery system with vented mouthpiece
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7459146B2 (en) 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
AU2004246819A1 (en) 2003-06-13 2004-12-23 Nycomed Gmbh Formoterol and ciclesonide combination
SE527200C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE527069C2 (sv) * 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
SE527189C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050043343A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
CA2538237A1 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
PT1670482E (pt) 2003-09-16 2014-03-12 Takeda Gmbh Utilização de ciclesonida para o tratamento de doenças respiratórias
BRPI0415707A (pt) * 2003-10-20 2006-12-19 Schering Corp composições farmacêuticas
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
JP5209963B2 (ja) 2004-07-02 2013-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 噴霧剤としてｔｇ２２７ｅａ又はｔｇ１３４ａを含有するエアロゾル懸濁製剤
PE20061162A1 (es) * 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
KR20070100735A (ko) 2004-12-17 2007-10-11 씨아이피엘에이 엘티디. 약학적 화합물 및 조성물
WO2006101882A2 (en) * 2005-03-16 2006-09-28 Honeywell International Inc. Medicament delivery formulations, devices and methods
JP2008538758A (ja) * 2005-04-23 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬に加えてベータ受容体刺激薬及びステロイドを含有する吸入用の医薬組成物
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
KR20150041804A (ko) 2007-02-11 2015-04-17 맵 파마슈티컬스, 인코포레이티드 부작용 프로파일을 최소화하면서 편두통의 빠른 완화를 가능하게 하는 ｄｈｅ의 치료적 투여 방법
GB0712454D0 (en) 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
WO2009088553A1 (en) 2007-10-22 2009-07-16 Board Of Regents, The University Of Texas System Dry powder drug delivery formulations, methods of use, and devices therefore
US20110003897A1 (en) * 2007-11-02 2011-01-06 Wayne State University Methods of engineering polar drug particles with surface-trapped hydrofluoroalkane-philes
US8227027B2 (en) 2007-12-07 2012-07-24 Presspart Gmbh & Co. Kg Method for applying a polymer coating to an internal surface of a container
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
KR101719824B1 (ko) 2008-05-09 2017-04-04 호라이라 인코포레이티드 기관지나무 치료용 시스템, 어셈블리 및 방법
PE20150621A1 (es) 2009-01-23 2015-05-07 Rigel Pharmaceuticals Inc Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
WO2010141834A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
EP2926757B1 (en) 2009-10-27 2023-01-25 Nuvaira, Inc. Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
AU2010319477A1 (en) 2009-11-11 2012-05-24 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
US20130102591A1 (en) 2010-01-26 2013-04-25 Andrew Lurie Salzman Compositions and methods for prevention and treatment of pulmonary hypertension
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
JP2014519519A (ja) 2011-06-15 2014-08-14 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規３，４，４ａ，１０ｂ−テトラヒドロ−１Ｈ−チオピラノ［４，３−ｃ］イソキノリン化合物
US20140112945A1 (en) 2011-06-17 2014-04-24 Takeda Gmbh Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
GB201118188D0 (en) * 2011-10-21 2011-12-07 3M Innovative Properties Co Manufacture of medicinal aerosol canisters
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
WO2013142038A2 (en) 2012-03-23 2013-09-26 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
RU2494730C1 (ru) * 2012-03-27 2013-10-10 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения болезней органов дыхания, содержащий в качестве активных веществ микронизированный салметерол ксинофоат и микронизированный флутиказона пропионат и способ его получения
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
EP3174522A1 (en) 2014-07-29 2017-06-07 3M Innovative Properties Company Method of preparing a pharmaceutical composition
WO2018069210A1 (en) 2016-10-10 2018-04-19 Takeda Gmbh Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4
US10702495B2 (en) 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
EP3750528A1 (en) 2019-06-11 2020-12-16 Nexien Biopharma, Inc. Compositions for treating dystrophies and myotonia
JP2022543843A (ja) 2019-08-08 2022-10-14 ライジェル ファーマシューティカルズ， インコーポレイテッド サイトカイン放出症候群を治療するための化合物及び方法
EP4013420B1 (en) 2019-08-14 2023-11-01 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
TW202346291A (zh) 2022-03-23 2023-12-01 美商雷傑製藥公司 作為ｉｒａｋ抑制劑的嘧啶—２—基—吡唑化合物

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (hu) * 1956-03-21 1900-01-01
US2885427A (en) * 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
BE556587A (hu) * 1957-01-31 1957-04-11
NL289785A (hu) † 1962-11-29
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
US3261748A (en) 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
US4044126A (en) * 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US3897779A (en) * 1973-06-27 1975-08-05 American Cyanamid Co Triamcinolone acetonide inhalation therapy
US3809294A (en) * 1973-06-27 1974-05-07 American Cyanamid Co Dispensing lung contacting powdered medicaments
US4044125A (en) * 1975-07-18 1977-08-23 Eli Lilly And Company Method of stabilizing acetylsalicylic acid in the presence of d-propoxyphene hydrochloride and compositions thereof
FI770215A (hu) * 1976-01-30 1977-07-31 Fisons Ltd
US4405598A (en) * 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
NL7708731A (nl) † 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US4116370A (en) * 1976-12-27 1978-09-26 Spitzer Joseph G Vapor tap valve for aerosol containers used with flammable propellants
BE887518A (fr) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
GB2088877B (en) † 1980-02-15 1984-07-04 Glaxo Group Ltd Androstane 17 carbothioates
US4578221A (en) 1980-04-23 1986-03-25 Glaxo Group Limited Androstane carbothioic acids
FI63672C (fi) * 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
GB8820398D0 (en) 1988-08-27 1988-09-28 Fisons Plc Pharmaceutical formulation
GB8828477D0 (en) † 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
DE3905726A1 (de) * 1989-02-24 1990-08-30 Hoechst Ag Druckgaspackung und treibmittel fuer aerosole
US4940171A (en) * 1989-05-18 1990-07-10 Gilroy Gordon C Aerosol package having compressed gas propellant and vapor tap of minute size
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
GB2235627B (en) † 1989-09-08 1993-09-01 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
GB8921222D0 (en) † 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4003270A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
DE69131867T2 (de) * 1990-03-23 2000-05-18 Minnesota Mining And Mfg. Co., Saint Paul Anwendung von löslichen fluorhaltigen Tensiden zur Herstellung von Aerosol-Präparaten mit dosierter Abgabe
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
IL98639A0 (en) * 1990-06-28 1992-07-15 Glaxo Inc Aerosol drug formulations
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
ES2096653T3 (es) * 1990-06-29 1997-03-16 Fisons Plc Composiciones de aerosol presurizado.
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
ES2064160T3 (es) * 1990-10-18 1995-01-16 Minnesota Mining & Mfg Formulacion de aerosol que comprende 17,21-dipropionato de beclometasona.
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9024365D0 (en) † 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) † 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
JPH04316448A (ja) * 1991-04-12 1992-11-06 Iwatani Internatl Corp 人参微粉末の製造方法
EP1736147A3 (en) * 1991-06-10 2007-10-17 Schering Corporation Non-chlorofluorocarbon aerosol formulations
ES2200771T3 (es) * 1991-06-10 2004-03-16 Schering Corporation Formulaciones en aerosol no clorofluorocarbonadas.
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5744123A (en) 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
JP3280974B2 (ja) * 1991-12-12 2002-05-13 グラクソ、グループ、リミテッド 医 薬
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
CA2421976C (en) * 1991-12-12 2004-04-20 Glaxo Group Limited Medicaments
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
EP0617610B1 (en) * 1991-12-18 1997-03-19 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
US20030103907A1 (en) * 1991-12-18 2003-06-05 Schultz Robert K. Suspension aerosol formulations
US5202110A (en) * 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5833950A (en) 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
JPH0855956A (ja) 1994-08-10 1996-02-27 Fuji Electric Co Ltd 駆動回路装置モジュール
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
GB9510750D0 (en) 1995-05-26 1995-07-19 Zeneca Ltd Chemical process
US5603918A (en) * 1995-06-09 1997-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Aerosol composition of a salt of ipratropium and a salt of albuterol
TW382127B (en) * 1996-08-30 2000-02-11 Sony Corp Magnetic recording medium and cleaning tape
US6306396B1 (en) * 1996-10-01 2001-10-23 Corixa Corporation Compounds and methods for the diagnosis and treatment of B. microti infection
BR0208012A (pt) * 2001-03-20 2004-03-02 Glaxo Group Ltd Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma

Also Published As

Publication number Publication date
AP9200461A0 (en) 1993-01-31
US6238647B1 (en) 2001-05-29
BG98803A (bg) 1995-02-28
AP402A (en) 1995-08-22
EP1275375A1 (en) 2003-01-15
ATE296617T1 (de) 2005-06-15
PT1287820E (pt) 2009-03-11
NO20001227D0 (no) 2000-03-09
ES2319873T3 (es) 2009-05-14
ATE373465T1 (de) 2007-10-15
DE69231857T2 (de) 2001-11-29
NO20065102L (no) 1994-06-10
DE69232856D1 (de) 2003-01-02
EP0990437A1 (en) 2000-04-05
AU663904C (en) 2005-05-19
IS3957A (is) 1993-06-13
DE69232856T2 (de) 2003-07-31
US20090188491A1 (en) 2009-07-30
EP0990437B1 (en) 2002-11-20
NO307864B1 (no) 2000-06-13
CY2591B2 (en) 2009-11-04
CA2447510A1 (en) 1993-06-24
PT1066828E (pt) 2003-10-31
ATE163539T1 (de) 1998-03-15
CY2493B1 (en) 2005-09-02
EP0616523A1 (en) 1994-09-28
DE69231857D1 (de) 2001-07-05
ATE240716T1 (de) 2003-06-15
ES2158988T3 (es) 2001-09-16
ATE201587T1 (de) 2001-06-15
CY2134B1 (en) 2002-06-21
DE69232856T3 (de) 2009-07-09
EP1287820B1 (en) 2009-01-21
SK279920B6 (sk) 1999-05-07
DE69233519D1 (de) 2005-07-07
US20050089477A1 (en) 2005-04-28
DK1440686T3 (da) 2008-01-21
US5676929A (en) 1997-10-14
NO20001227L (no) 1994-06-10
CA2447510C (en) 2007-07-03
DE69233712D1 (de) 2007-10-31
ES2188092T3 (es) 2003-06-16
DK1275375T3 (da) 2005-08-22
ATE421315T1 (de) 2009-02-15
IL104068A0 (en) 1993-05-13
DK0616523T3 (da) 1998-09-28
PT1275375E (pt) 2005-09-30
JPH07502033A (ja) 1995-03-02
ES2199739T5 (es) 2007-06-16
HUT67534A (en) 1995-04-28
EP0616523B1 (en) 1998-03-04
DE69224656T2 (de) 1998-07-23
BG102689A (en) 1999-02-26
DE69233076T3 (de) 2007-07-12
RU94030722A (ru) 1996-10-20
OA09926A (en) 1994-09-15
ES2242823T3 (es) 2005-11-16
US20030143163A1 (en) 2003-07-31
EP1066828B2 (en) 2006-12-06
IS1709B (is) 1998-12-16
JPH11310533A (ja) 1999-11-09
EP1287820A1 (en) 2003-03-05
DK1066828T4 (da) 2007-02-26
NO942185D0 (no) 1994-06-10
AU3085092A (en) 1993-07-19
DE69224656D1 (de) 1998-04-09
RU2179037C2 (ru) 2002-02-10
GEP20002253B (en) 2000-10-25
DE69233519T2 (de) 2006-04-27
EP0990437B2 (en) 2008-10-22
DE122006000020I1 (de) 2011-12-01
US20020028183A1 (en) 2002-03-07
HU227681B1 (en) 2011-11-28
HK1012988A1 (en) 1999-08-13
DE69233712T2 (de) 2008-06-19
CA2402300A1 (en) 1993-06-24
ES2113444T3 (es) 1998-05-01
HU211671A9 (en) 1995-12-28
CA2125667C (en) 2000-06-13
CA2586146C (en) 2009-01-20
CY2441B1 (en) 2004-11-12
HK1054500B (zh) 2005-12-30
EP1440686B1 (en) 2007-09-19
GR3036476T3 (en) 2001-11-30
DK0990437T4 (da) 2009-02-16
ATE227975T1 (de) 2002-12-15
MX9207205A (es) 1993-11-01
US20040136920A1 (en) 2004-07-15
CA2362539C (en) 2003-02-04
BG64539B1 (bg) 2005-07-29
US6303103B1 (en) 2001-10-16
CA2303685C (en) 2002-02-12
HU227383B1 (en) 2011-05-30
RU2129424C1 (ru) 1999-04-27
DE69233076T2 (de) 2004-03-18
CA2586146A1 (en) 1993-06-24
ES2294386T3 (es) 2008-04-01
KR100278339B1 (ko) 2001-01-15
HU0800468D0 (en) 2008-09-29
ES2199739T3 (es) 2004-03-01
WO1993011743A1 (en) 1993-06-24
JP3026840B2 (ja) 2000-03-27
EP1066828A1 (en) 2001-01-10
DK1287820T3 (da) 2009-05-18
EP1066828B1 (en) 2003-05-21
ES2188092T5 (es) 2009-04-01
EP1440686A1 (en) 2004-07-28
EP0756868B1 (en) 2001-05-30
DK0990437T3 (da) 2003-03-10
EP1857101A3 (en) 2008-10-08
PT1440686E (pt) 2007-12-19
CY2602B2 (en) 2010-03-03
DE69233076D1 (de) 2003-06-26
CZ143094A3 (en) 1995-03-15
CA2303685A1 (en) 1993-06-24
AU663904B2 (en) 1995-10-26
HK1004711A1 (en) 1998-12-04
CA2125667A1 (en) 1993-06-24
PT756868E (pt) 2001-11-30
EP1275375B1 (en) 2005-06-01
NO325422B1 (no) 2008-04-21
EP0756868A3 (en) 1997-02-26
DK1066828T3 (da) 2003-08-25
SK67494A3 (en) 1995-03-08
US5674472A (en) 1997-10-07
NZ246044A (en) 1996-01-26
EP1066828B9 (en) 2008-03-26
EP0756868A2 (en) 1997-02-05
HK1054500A1 (en) 2003-12-05
CY2566B1 (en) 2008-07-02
DK0756868T3 (da) 2001-09-10
TW232654B (hu) 1994-10-21
BG62119B1 (bg) 1999-03-31
MY109758A (en) 1997-06-30
DE69233755D1 (de) 2009-03-12
US7498020B2 (en) 2009-03-03
EP1857101A2 (en) 2007-11-21
PT990437E (pt) 2003-04-30
CZ287039B6 (cs) 2000-08-16
US6251368B1 (en) 2001-06-26
NO942185L (hu) 1994-06-10
IL104068A (en) 1998-10-30
CA2362539A1 (en) 1993-06-24
CA2402300C (en) 2005-06-28
CA2654849A1 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
HU9401742D0 (en) Medicaments for inhalation
IL101289A0 (en) Inhaler for solid medicaments
IL102322A0 (en) Medicaments
HK220596A (en) Inhalation device for powdered medicaments
GB9115740D0 (en) Medicaments
GB9108348D0 (en) Medicaments
GB9104650D0 (en) Medicaments
ZA927925B (en) Medicaments
GB9108349D0 (en) Medicaments
GB9122475D0 (en) Medicaments
GB9113379D0 (en) Medicaments
ZA929617B (en) Medicaments
GB9112675D0 (en) Medicaments
GB9112581D0 (en) Medicaments
ZA924524B (en) Medicaments
GB9112539D0 (en) Medicaments
GB9111901D0 (en) Medicaments
GB9126444D0 (en) Medicaments
GB9126405D0 (en) Medicaments
GB9113381D0 (en) Medicaments
GB9113383D0 (en) Medicaments
GB9113787D0 (en) Medicaments
GB9113788D0 (en) Medicaments
GB9122473D0 (en) Medicaments
GB9122472D0 (en) Medicaments